Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.

Microbix makes biotherapeutic drugs, vaccines, and infectious disease diagnostics for multinational manufacturers. The company's pipeline includes leading generic drug candidate ThromboClear for the treatment of coronary artery thrombosis and the FDA-approved drug urokinase, used to treat pulmonary embolism. Microbix has also submitted patents for its Sperm Sexing Technology, which enables livestock producers to predetermine offspring gender prior to conception. In 2008 Microbix entered into an agreement with China to build one of the world's largest influenza manufacturing plants to produce flu vaccines.

Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug candidate tesamorelin is a growth hormone-releasing peptide that Theratechnologies believes can combat a variety of problems, including HIV-related lipodystrophy (the metabolic syndrome characterized by changes in distribution of adipose tissue), muscle wasting associated with chronic obstructive pulmonary disease, sleep maintenance insomnia, and immune dysfunction in elderly patients.

Endocyte, Inc. company was founded in 1996 and is based in West Lafayette, Indiana. Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers.

QuA Vodis aims to help biotechnology and pharmaceutical companies get where they are going. The company, whose name shouldn't be confused with the movie Quo Vadis, offers interim management, quality assurance system development and training, and regulatory assistance to firms engaged in human and veterinary medical research. Its main focus for consultations is to enable the organizations to maintain operations and quality with as little internal disruption as possible. QuA Vodis has experience working with products such as sterile injectibles, radiopharmaceuticals, and blood and tissue products.

Capellon was founded in 1999. Capellon Pharmaceuticals is helping curb the common cold. Capellon Pharmaceuticals company's product portfolio includes Liquibid, Rescon, and Tussi-bid, prescription remedies for cough and congestion. Other products target various allergies as well as respiratory, gastrointestinal, and bladder ailments. Capellon concentrates its efforts on marketing products it already has and acquiring products useful to it current customer base. With an intense focus on growth it looks for partners with whom it can co-promote new drugs whenever possible.

MPI Research was founded in 1962. MPI Research helps drug developers answer a crucial question: Is it safe? The contract research organization (CRO) specializes in providing pre-clinical research services to pharmaceutical, medical device, chemical, and agricultural development companies, as well as regulatory and other government agencies. Its toxicology testing services investigate and determine the safety and dosage levels of substances being considered for use in drugs, pesticides, petrochemicals, and food additives. MPI Research also offers contract bioanalytical and pharmacology services.

Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.

Æterna Zentaris Inc. company was founded in 1991 and is headquartered in Quebec, Canada. Æterna Zentaris Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for endocrine therapy and oncology. Its lead product candidates in endocrinology are cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that has completed Phase III trial for benign prostatic hyperplasia (BPH); and AEZS-130, an oral ghrelin antagonist in a Phase III trial as a diagnostic test for Growth Hormone Deficiency. Æterna Zentaris company's lead products in cancer are perifosine, a PI3K/Akt pathway inhibitor in Phase III for multiple myeloma, and AEZS-108, a Phase II clinical trial product for the treatment of advanced ovarian and endometrial cancers, as well as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma. Its pipeline also include compounds in pre clinical development, such as AEZS-115, an LHRH antagonist for endometriosis and urology; AEZS-120, an anti-cancer vaccine; AEZS-126 Erk and PI3K inhibitors for oncology; and AEZS-127 ErPC for oncology. Æterna Zentaris has partnership agreements with Shionogi and Co.; sanofi-aventis; Nippon Kayaku Co. Ltd.; Spectrum Pharmaceuticals, Inc.; Handok Pharmaceuticals Co., Ltd.; and Keryx Biopharmaceuticals, Inc.

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Its pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures. The company's product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of glioblastoma multiforme and metastatic melanoma; MPC-4326 for HIV-1 infection under Phase IIb clinical trial; and MPC-3100, a Phase I clinical trial product candidate for cancer treatment. Its products in preclinical programs comprise MPI-443803, an orally available, brain penetrant, microtubule destabilizing agent for the treatment of cancer; and MPI-461359, an orally available maturation inhibitor for the treatment of HIV-1 infection, as well as MPI-479605 for the treatment of cancer. The company also offers ProNet, a proprietary database of protein-protein interactions, which encompasses interactions between approximately 10 million protein fragments constructed from various organ tissues, including heart, brain, kidney, liver, breast, and prostate. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.